Transferring prime editor manufacturing processes for Advanced Therapy Medicinal Product (ATMP) production requires a level of analytical and procedural rigor that exceeds conventional templates. The complexity of the prime editor ribonucleoprotein (RNP) complex and its delivery vehicle demands a purpose-built strategy focused on identifying and controlling key quality attributes (CQAs) from the outset. A robust tech transfer framework, grounded in phase-appropriate analytics and scalable production platforms, is necessary to ensure product consistency and support harmonized regulatory submissions for the FDA, EMA, and Swissmedic.

Frequently Asked Questions

Q: What are the primary CMC challenges when transferring prime editor manufacturing processes for ATMP production?

The main challenges involve ensuring the consistent quality and integrity of the large prime editing guide RNA (pegRNA) and the prime editor (PE) enzyme, often delivered via lipid nanoparticles (LNPs) or viral vectors. Establishing robust analytical methods to characterize the final product and control for process-related impurities is a key hurdle for successful Investigational Medicinal Product Dossier (IMPD) submissions.

Q: How does Franklin Biolabs ensure process robustness for novel gene editing systems during tech transfer?

We establish a deep analytical foundation early in development. By defining key quality attributes and implementing phase-appropriate GxP analytics, we create a data-driven process that is scalable and transferable. This approach is built on the deep experience of our core scientific team, which has contributed to a 100% successful IND rate since 2019, even as Franklin Biolabs formally launched in 2024.

Q: For a program targeting both US and Swiss markets, how do you manage regulatory documentation for tech transfer?

Our process development and tech transfer packages are designed from the ground up to align with harmonized international guidelines (ICH). We generate comprehensive documentation suitable for multi-jurisdictional submissions, ensuring data integrity and traceability for both IND and IMPD filings, streamlining the path to global clinical trials.

Aligning Prime Editor Process Development with Global Regulatory Expectations

Proven Intelligence in Advanced Therapy Manufacturing.

Transferring a manufacturing process for a prime editor therapeutic requires the systematic translation of scientific understanding into a controlled, repeatable, and scalable GxP operation. For sponsors targeting approvals in Switzerland and other global jurisdictions, this requires a partner with demonstrated experience in navigating the complexities of ATMP characterization and manufacturing.

Prime editing systems, with their large pegRNA and reverse transcriptase components, introduce unique manufacturing variables. Minor deviations in upstream production or downstream purification can significantly impact the quality, activity, and safety profile of the final product. This sensitivity underscores the need for a robust process control strategy established long before scale-up begins.

The High Cost of Process Variability

Historical data from earlier next-generation therapeutics illustrates the risk of uncontrolled biological responses. Early adenoviral vector programs, for instance, revealed that insufficient understanding of the host immune response could lead to severe adverse events, even when preclinical models suggested a favorable profile (PMID: 14567964). Subsequent work showed that even at lower doses, inconsistent vector activity and expression levels could prevent meaningful metabolic correction, undermining the therapeutic hypothesis (PMID: 11779420).

These lessons directly inform our approach to prime editor manufacturing. An inadequately controlled process can introduce impurities or product variants that trigger unintended immunological reactions or result in inconsistent editing efficiency. Our focus is on building a process with minimal variability, supported by high-resolution analytics to ensure each batch meets predefined specifications. This proactive de-risking is central to achieving the typical 18-24 month timeline to IND.

A Framework for Seamless Technology Transfer

A successful tech transfer relies on continuity and deep institutional knowledge. The process must be managed by a team that understands the nuances of the modality and the history of the specific program.

The transition of key scientific personnel from established academic vector cores to Franklin Biolabs provides seamless continuity for client programs. This model ensures that institutional knowledge is retained, allowing our team to function as an integrated scientific collaborator and maintain momentum in AAV-vector based gene therapy candidate development without interruption.

This seamless transition of expertise is what enables process integrity. Our framework for prime editor tech transfer includes:

• Phase-Appropriate Analytical Qualification: Implementing and qualifying assays for identity, purity, strength, and activity that are suitable for the development stage.
• Scalability Assessment: Evaluating the process for scalability from bench-scale to the larger volumes required for extensive preclinical studies and clinical trials.
• Comprehensive Documentation: Generating detailed batch records, development reports, and validation protocols that satisfy global regulatory bodies.

By embedding this rigor early, we equip sponsors with a manufacturing process prepared for the demands of multi-center, international clinical programs.

Back to Parent Hub: Vector | CMC | Analytics Services

---

---